Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)
Public ClinicalTrials.gov record NCT00391066. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized (1:1), open-label, multicenter, active-controlled study in patients with previously treated CD23+ and CD20+ relapsed CLL. Patients will receive treatment with either lumiliximab in combination with FCR or FCR alone.
Study identification
- NCT ID
- NCT00391066
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 627 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2006 (Type not available)
- Primary completion
- Jul 2010 (Actual)
- Completion
- Dec 2010 (Actual)
- Last update posted
- Oct 2, 2015
2006 – 2010
United States locations
- U.S. sites
- 53
- U.S. states
- 23
- U.S. cities
- 53
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | — | — |
| Research Site | Alhambra | California | — | — |
| Research Site | Burbank | California | — | — |
| Research Site | Fullerton | California | — | — |
| Research Site | La Jolla | California | — | — |
| Research Site | Long Beach | California | — | — |
| Research Site | Los Angeles | California | — | — |
| Research Site | Northridge | California | — | — |
| Research Site | Oxnard | California | — | — |
| Research Site | Pomona | California | — | — |
| Research Site | Redondo Beach | California | — | — |
| Research Site | Sacramento | California | — | — |
| Research Site | Santa Maria | California | — | — |
| Research Site | Fort Myers | Florida | — | — |
| Research Site | Atlanta | Georgia | — | — |
| Research Site | Marietta | Georgia | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Maywood | Illinois | — | — |
| Research Site | Indianapolis | Indiana | — | — |
| Research Site | Overland Park | Kansas | — | — |
| Research Site | Shreveport | Louisiana | — | — |
| Research Site | Boston | Massachusetts | — | — |
| Research Site | Detroit | Michigan | — | — |
| Research Site | Saint Joseph | Michigan | — | — |
| Research Site | Ypsilant, | Michigan | — | — |
| Research Site | Minneapolis | Minnesota | — | — |
| Research Site | Columbia | Missouri | — | — |
| Research Site | St Louis | Missouri | — | — |
| Research Site | Billings | Montana | — | — |
| Research Site | Omaha | Nebraska | — | — |
| Research Site | Hackensack | New Jersey | — | — |
| Research Site | Morristown | New Jersey | — | — |
| Research Site | Chapel Hill | North Carolina | — | — |
| Research Site | Raleigh | North Carolina | — | — |
| Research Site | Columbus | Ohio | — | — |
| Research Site | Kettering | Ohio | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Pittsburgh | Pennsylvania | — | — |
| Research Site | Greenville | South Carolina | — | — |
| Research Site | Nashville | Tennessee | — | — |
| Research Site | Austin | Texas | — | — |
| Research Site | Bedford | Texas | — | — |
| Research Site | Dallas | Texas | — | — |
| Research Site | Fort Worth | Texas | — | — |
| Research Site | Fredericksburg | Texas | — | — |
| Research Site | Houston | Texas | — | — |
| Research Site | San Antonio | Texas | — | — |
| Research Site | Norfolk | Virginia | — | — |
| Research Site | Roanoke | Virginia | — | — |
| Research Site | Kennewick | Washington | — | — |
| Research Site | Saint Louis | Washington | — | — |
| Research Site | Spokane | Washington | — | — |
| Research Site | Yakima | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 141 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00391066, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2015 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00391066 live on ClinicalTrials.gov.